Logo image of NRXP

NRX PHARMACEUTICALS INC (NRXP) Stock Fundamental Analysis

USA - NASDAQ:NRXP - US6294442099 - Common Stock

3.02 USD
-0.03 (-0.98%)
Last: 10/30/2025, 8:00:02 PM
3.01 USD
-0.01 (-0.33%)
After Hours: 10/30/2025, 8:00:02 PM
Fundamental Rating

1

Taking everything into account, NRXP scores 1 out of 10 in our fundamental rating. NRXP was compared to 192 industry peers in the Pharmaceuticals industry. NRXP may be in some trouble as it scores bad on both profitability and health. NRXP is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NRXP has reported negative net income.
NRXP had a negative operating cash flow in the past year.
In the past 5 years NRXP always reported negative net income.
NRXP had a negative operating cash flow in each of the past 5 years.
NRXP Yearly Net Income VS EBIT VS OCF VS FCFNRXP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -698.51%, NRXP is not doing good in the industry: 94.79% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -698.51%
ROE N/A
ROIC N/A
ROA(3y)-418.16%
ROA(5y)-467.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NRXP Yearly ROA, ROE, ROICNRXP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NRXP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NRXP Yearly Profit, Operating, Gross MarginsNRXP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

NRXP has less shares outstanding than it did 1 year ago.
The number of shares outstanding for NRXP has been increased compared to 5 years ago.
The debt/assets ratio for NRXP is higher compared to a year ago.
NRXP Yearly Shares OutstandingNRXP Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
NRXP Yearly Total Debt VS Total AssetsNRXP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

NRXP has an Altman-Z score of -104.67. This is a bad value and indicates that NRXP is not financially healthy and even has some risk of bankruptcy.
NRXP has a worse Altman-Z score (-104.67) than 95.31% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -104.67
ROIC/WACCN/A
WACCN/A
NRXP Yearly LT Debt VS Equity VS FCFNRXP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 0.11 indicates that NRXP may have some problems paying its short term obligations.
NRXP's Current ratio of 0.11 is on the low side compared to the rest of the industry. NRXP is outperformed by 96.35% of its industry peers.
A Quick Ratio of 0.11 indicates that NRXP may have some problems paying its short term obligations.
The Quick ratio of NRXP (0.11) is worse than 96.35% of its industry peers.
Industry RankSector Rank
Current Ratio 0.11
Quick Ratio 0.11
NRXP Yearly Current Assets VS Current LiabilitesNRXP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 45.59% over the past year.
EPS 1Y (TTM)45.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NRXP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.64% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y87.64%
EPS Next 2Y48.43%
EPS Next 3Y46.08%
EPS Next 5Y34.64%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NRXP Yearly Revenue VS EstimatesNRXP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
NRXP Yearly EPS VS EstimatesNRXP Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4 -6

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NRXP. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 6.44, the valuation of NRXP can be described as very cheap.
Based on the Price/Forward Earnings ratio, NRXP is valued cheaper than 93.23% of the companies in the same industry.
NRXP's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.50.
Industry RankSector Rank
PE N/A
Fwd PE 6.44
NRXP Price Earnings VS Forward Price EarningsNRXP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NRXP Per share dataNRXP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as NRXP's earnings are expected to grow with 46.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.43%
EPS Next 3Y46.08%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NRXP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NRX PHARMACEUTICALS INC

NASDAQ:NRXP (10/30/2025, 8:00:02 PM)

After market: 3.01 -0.01 (-0.33%)

3.02

-0.03 (-0.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-18 2025-08-18/bmo
Earnings (Next)11-12 2025-11-12
Inst Owners25.47%
Inst Owner Change0.4%
Ins Owners7.5%
Ins Owner Change0%
Market Cap71.79M
Revenue(TTM)N/A
Net Income(TTM)-33794000
Analysts84
Price Target36.98 (1124.5%)
Short Float %4.36%
Short Ratio1.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9.05%
Min EPS beat(2)-49.47%
Max EPS beat(2)31.37%
EPS beat(4)2
Avg EPS beat(4)-19.1%
Min EPS beat(4)-138.39%
Max EPS beat(4)80.09%
EPS beat(8)5
Avg EPS beat(8)-4.18%
EPS beat(12)7
Avg EPS beat(12)-3.15%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)27.19%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.01%
EPS NY rev (1m)0%
EPS NY rev (3m)-124%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-10.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-19.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 6.44
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.42
EYN/A
EPS(NY)0.47
Fwd EY15.54%
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.5
OCFYN/A
SpS0
BVpS-1.5
TBVpS-1.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -698.51%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-418.16%
ROA(5y)-467.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.11
Quick Ratio 0.11
Altman-Z -104.67
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)103.33%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.73%
EPS Next Y87.64%
EPS Next 2Y48.43%
EPS Next 3Y46.08%
EPS Next 5Y34.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y39.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.64%
EBIT Next 3Y140.89%
EBIT Next 5Y95.9%
FCF growth 1Y58.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.18%
OCF growth 3YN/A
OCF growth 5YN/A

NRX PHARMACEUTICALS INC / NRXP FAQ

What is the ChartMill fundamental rating of NRX PHARMACEUTICALS INC (NRXP) stock?

ChartMill assigns a fundamental rating of 1 / 10 to NRXP.


What is the valuation status for NRXP stock?

ChartMill assigns a valuation rating of 4 / 10 to NRX PHARMACEUTICALS INC (NRXP). This can be considered as Fairly Valued.


What is the profitability of NRXP stock?

NRX PHARMACEUTICALS INC (NRXP) has a profitability rating of 0 / 10.


Can you provide the financial health for NRXP stock?

The financial health rating of NRX PHARMACEUTICALS INC (NRXP) is 0 / 10.